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Abstract
Background In clinical practice, non-medical switching of biological medicationmay provoke nocebo effects due to unexplained
deterioration of therapeutic benefits. Indication extrapolation, idiosyncratic reactions, and interchangeability remain challenged
in clinical practice after biosimilar approval by the European Medicines Agency. The principle of Bfirst do no harm^ may be
challenged in a patient when switching from originator to biosimilar biological.
Aim To describe the 1-year results of a pragmatic study on infliximab biosimilar implementation in immune-mediated inflam-
matory disease patients on the basis of shared decision-making under effectiveness and safety monitoring.
Methods Inflammatory bowel disease and rheumatology patients on infliximab originator were converted to infliximab
biosimilar after providing informed consent. Nocebo response patients were monitored after switch back to originator. Linear
mixed models were used to analyze continuous endpoints on effectiveness and laboratory outcomes to determine significance
(P ≤ 0.05) of change over time after switching.
Results After inviting 146 patients, a group of 125 patients enrolled in the project over time, respectively, 73 Crohn’s disease, 28
ulcerative colitis, nine rheumatoid arthritis, ten psoriatic arthritis, and five ankylosing spondylitis patients. No statistically
significant changes in effectiveness and safety were observed in any of the indications after a median of 4 infusions in 9 months
of study. An overall nocebo response of 12.8% was found among the patients during a minimal observation period of 6 months
after the transition to biosimilar infliximab. The overall nocebo response rate did not differ between the studied indications.
Conclusions In inflammatory bowel disease and rheumatological patients, similar effectiveness and safety were demonstrated on
the transition into infliximab biosimilar. In our series, patient empowerment and registration of treatment outcomes delineated
biosimilar transition, an approach that hypothetically could reduce nocebo response rates which are relevant to account for
regarding biosimilar implementation.
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Introduction
In 2013, the European Medicines Agency approved mono-
clonal antibody infliximab biosimilar, based on pharmaco-
logical similarity and safety results. In the approval process
of infliximab, biosimilar preclinical similarity testing was
emphasized, followed by a limited program of clinical
comparability confirmation studies in rheumatoid arthritis
and ankylosing spondylitis patients [1]. Based on the re-
sults of these adapted registration studies, comparable ef-
fectiveness and safety were concluded for infliximab
biosimilar [2]. Nevertheless, clinical concerns were being
raised concerning indication extrapolation, safety and idi-
osyncratic adverse drug reactions, and issues of substitu-
tion and interchangeability.
More recently, it was shown in the NORSWITCH study
that non-inferiority of infliximab biosimilar was likely if com-
pared to infliximab originator against a margin of 15% [3].
Both this study as well as the European Medicines Agency
approval remain however challenged as being sufficient for
gaining full trust in the treatment practice of medical doctors
and their patients, subsequently. Clinical concerns in case of
applying (biosimilar) biologicals are partly based on the ex-
trapolation of the indication denying potential variance in
pharmacokinetics and pharmacodynamics over time [4].
Indeed, one may raise concerns with respect to non-medical
switching and/or interchangeability whether the principle of
Bfirst do no harm (primum nil nocere)^ is challenged in an
individual patient on treatment with a(n) (originator) biologi-
cal (with for that person proven and documented effectiveness
and safety). Therefore, in Dutch treatment guidelines, it has
been stated that biosimilars should only be implemented in
naïve patients or in treated patients following informed con-
sent under close monitoring of effectiveness and safety, pref-
erably in a clinical study [5–7].
In clinical practice, non-medical switching may induce
nocebo effects, i.e., unexplained detrimental therapeutic ef-
fects. This underlines that in any switching study so far, the
second biological drug, thus even biosimilar ones, exerts less
therapeutic benefit due to unexplained but nevertheless
existing patients’ concerns about value and effect of a drug
[8]. For this reason, shared decision-making between doctor
and patient remains essential, specifically when pure econom-
ic aspects of biological use may tend to prevail. Relevant
practical issues that cannot be fully tackled or facilitated in
practice are the traceability of biologicals on the level of med-
ication batch numbers, and the use of the correct brand name
(usually being the generic name, e.g., infliximab, more than
Remicade®, Remsima®, Inflectra®, or Flixabi®) which is
necessary for proper pharmacovigilance in order to designate
any adverse drug reactions to the correct drug brand or batch
or sequence of various drug brands being applied in a single,
unique patient.
These uncertainties, accompanied by medical concerns,
have to be tackled by a critical healthcare professional who
is not always familiar with the pharmacological finesses of
large protein drugs or their biosimilars. Therefore, biophar-
maceutical products should be implemented with appropri-
ate criticism with concomitant monitoring of treatment
quality, and patients’ benefit, allowing for evidence-based
treatment decision, preferably in a setting with shared
decision-making between physician and patient, more than
on cost efficiency only.
In this paper, we aimed to describe infliximab biosimilar
implementation in IBD and rheumatology practice, guided by
effectiveness and safety monitoring, and particularly focusing
on the nocebo response to quantify patients’ acceptance. We
present the 1-year results of a pragmatic trial performed in the
period between July 2016 and April 2017.
Patients and methods
The switch protocol of originator to biosimilar infliximab was
written by a consensus team (NB, MR, RP, AAvB) with man-
date of the team of gastroenterologists, rheumatologists, and
clinical pharmacists familiar with the concept of biosimilars.
The protocol was reviewed by the local medical ethics com-
mittee as an observational study in clinical routine and was in
accordance with guidelines for non-medical switching into
biosimilars of the Dutch Society of Gastroenterologists,
Dutch Association of Rheumatology, the Dutch Society for
Consultants (FMS), and the Dutch Medicine Evaluation
Board (CBG) [5–7]. Patients with Crohn’s disease (CD), ul-
cerative colitis (UC), rheumatoid arthritis, psoriatic arthritis,
and ankylosing spondylitis were treated according to routine
practice and were followed during 7 infusions in this observa-
tional study. In this report we present the 1-year results.
Patient population
The therapy expectation following a possible non-medical
switch was communicated with patients by written documen-
tation first (provided as electronic supplement 1) and was
accompanied by oral clarification by the patients’ treating
physician or nurse practitioner when requested.
Patients providing informed consent voluntary agreed with
transition into infliximab biosimilar, this formal procedure
was used to emphasize that a non-medical driven change of
treatment was introduced in a shared decision-making fashion.
Participating patients were treated with infliximab according
to their usual dose and routine treatment interval. If patients
were switched back to originator infliximab for specific rea-
sons, they were still monitored during the project’s follow-up
period. The follow-up of patients was censored after switching
Eur J Clin Pharmacol
to other (biological) therapy due to non-response on
infliximab.
Consultants
The gastrointestinal and rheumatology consultants from a
large regional, referral hospital actively identified potential
participants from electronic patient records and by recruitment
on the day-care facility for infliximab administration. Positive
identification for participation was based on indication, adult-
hood, and the continuous treatment with infliximab originator.
Drug prescribing was managed via the electronic medication
system by brand name and the laboratory measurements dur-
ing the project were pre-ordered via the electronic patient dos-
sier. Patients that were included visited consultants and nurses
during the follow-up on alternating (routine) basis.
Data collection
A dedicated project database using Microsoft Excel (2013
Edition; Microsoft Corp, Redmond, WA, USA) was designed
for the retrospective collection of treatment outcome parame-
ters. Data on effectiveness was acquired via an online elec-
tronic patient questionnaires platform (Sermos e-
communication in healthcare) in which patients completed
the form during the infusion. This portal meets the data re-
quirements with ISO 9001/ISO 27001 certification. Safety
data were kept in the electronic patient file by the gastroenter-
ologists and rheumatologists and was related to the most re-
cent date of infusion. Laboratory measurements were ordered
according to routine care. IFX was prepared according to
standard local protocol with registration of individual batch
numbers with weekly update [9, 10]. Patients and treatment
characteristics and safety data were derived from the electron-
ic patient questionnaires platform, the patient’s file, medica-
tion prescription system, and the laboratory system—the
database.
Data acquisition
Monitoring parameters related to key issues in clinical
biosimilar implementation were defined as follows and mea-
sured before and after infliximab transition. Effectiveness and
safety were documented during every infusion visit. In both
IBD indications, pragmatically, patient’s assessment of dis-
ease activity on a 0–10 scale ranging from worse to good
was used. The Disease Activity Score 28-erythrocyte sedi-
mentation rate (DAS28-ESR) was used for effectiveness mea-
surements in rheumatoid arthritis and psoriatic arthritis [11].
The Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) was used for outcome measurements in ankylos-
ing spondylitis [12].
Generally, well-accepted laboratory assessments represen-
tative for disease activity in the investigated indications were
chosen. Pragmatically, in both IBD indications, fecal
calprotectin as a mucosal disease activity measure and C-
reactive protein (CRP) were analyzed. In rheumatology indi-
cations, both CRP and the erythrocyte sedimentation rate
(ESR) were assessed. Pharmacokinetics and immunogenicity
were monitored by measuring serum infliximab trough con-
centrations and the formation of neutralizing antibodies
against biosimilar or originator infliximab at trough. The
reporting of these test results was with delay for logistical
reasons. Infliximab serum concentration was measured using
a validated enzyme-linked immunosorbent assay (Sanquin
Laboratories, Amsterdam, NL) [13]. The free fraction of se-
rum neutralizing antibodies to infliximab was analyzed using
a validated radio immune-assay [14]. All laboratory measure-
ments were assessed per protocol before the first, second,
fourth, and seventh (biosimilar) infliximab infusion. In
Table 1, an overview of the assessments per indication is
provided.
A nocebo-effect response was defined as an unexplained,
unfavorable therapeutic effect subsequent to a non-medical
switch from originator infliximab to biosimilar infliximab
with regaining of the beneficial effects after reinitiating the
originator [8]. Nocebo effects were evaluated by the patient’s
treating physician. Patients were included at different time
points after the beginning of study. Nocebo response was cal-
culated in all patients who were included in the period be-
tween July 2016 and April 2017, with an observation period
of at least 6 months after the non-medical switch. The nocebo-
effect rate was calculated by dividing the number of patients
with a nocebo-effect response, by the number of all included
patients in the described period of 9 months.
Statistical considerations
All data are expressed as N (%) for categorical variables (un-
less specified otherwise) and as mean ± SD or median (inter-
quartile range, i.e., difference between 75th and 25th percen-
tiles) for numerical variables. Numerical endpoints on effec-
tiveness and laboratory outcomes were analyzed using linear
mixed models to assess their longitudinal effect, i.e., change
over time upon infliximab transition. For each diagnosis, CD,
UC, and ankylosing spondylitis separately and combined for
psoriatic arthritis and rheumatoid arthritis, we checked which
polynomial trend, i.e., cubic, quadratic, or linear trend, fitted
the data best using likelihood ratio tests. If the cubic and/or
quadratic trend was not significant, then a linear trend was
reported. A patient-specific random intercept was included
in the model to correct for repeated measures within a patient.
All available data have been used to determine and maximize
the likelihood [15]. The data analysis comprised collected data
from baseline and after each infliximab biosimilar infusion,
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irrespective of whether patients become nocebo-response pa-
tient or non-responder. All analyses were performed using
IBM SPSS Statistics for Windows (Version 23.0. Armonk,
NY: IBM Corp.). A P value smaller than or equal to 0.05
was considered statistically significant.
Results
In total, 146 patients were invited to participate in the period
between July 2016 and April 2017. A group of 125 (85.6%)
patients agreed and subsequently provided an informed con-
sent and enrolled in the study. The majority, 101 patients, had
IBD of whom 73 were diagnosed with CD and 28 patients
with UC. The rheumatologists enrolled nine, five, and ten
patients for rheumatoid arthritis, psoriatic arthritis, and anky-
losing spondylitis, respectively. Demographics and baseline
characteristics are depicted in Table 1. Unusual (serious) drug
reactions, that is, other than known in case of originator
infliximab therapy, were not reported. One patient with UC
(also treated with thioguanin and a medical history comprising
gallstone disease and excessive alcohol intake) without prior
history of pancreatitis died because of necrotizing pancreatitis
1 month after the last infusion with infliximab biosimilar. We
classified this as unrelated to infliximab use, based on clinical
presentation and the documented safety profile of infliximab,
and secondarily on the time lag between last infusion and this
adverse event. There was no causal relationship between ad-
verse drug reactions and/or neutralizing antibodies to
infliximab formation and the batch numbers used in the prep-
aration of the infusions.
Responders
Nine months after the start of the project, 61 (86.3%) CD
patients and 21 (78.6%) UC patients were on infliximab
biosimilar therapy after a median number of four infusions
for both indications.
Eight rheumatoid arthritis, five patients with psoriatic ar-
thritis, and eight ankylosing spondylitis patients were effec-
tively being treated with infliximab biosimilar after a median
number of three, four, and four infusions, respectively. No
neutralizing antibody against infliximab was observed in these
rheumatological indications.
Non-responders
Seven IBD patients ceased infliximab biosimilar therapy due
to ineffectiveness based on clinical presentation and laborato-
ry findings. This was observed in four patients with CD and
Table 1 Demographics and baseline values of Crohn’s disease (CD),
ulcerative colitis (UC), rheumatoid arthritis (RA), psoriatic arthritis
(PsoA), and ankylosing spondylitis (AS) patients on IFX originator
therapy. BASDAI bath ankylosing spondylitis disease activity index,
DAS28-ESR disease activity score 28-joint count, ESR erythrocyte
sedimentation rate, NAB neutralizing antibody
Demographics CD UC RA PsoA AS
Number of total included patients (%) 73/125 (58.4) 28/125 (22.4) 9/125 (7.2) 5/125 (4) 10/125 (8.0)
Age (years) 46.2 ± 15.3 46.0 ± 18.0 59 ± 10.1 59.2 ± 14.2 52.2 ± 9.5
Female participants (%) 58.9 46.4 66.7 80.0 30.0
Baseline characteristics
Infliximab treatment duration (years) 3.9 ± 1.4 3.5 ± 1.4 3.6 ± 1.4 2.9 ± 1.2 4.6 ± 0.5
Treatment interval of infliximab therapy (days) 46.4 ± 8.9 46.3 ± 9.1 46.2 ± 8.9 45.1 ± 9.0 45.5 ± 9.6
Concomitant immunosuppressive therapy (%)§ 32.8 32.1 88.9 100 0
Parameters at baseline
Patient’s assessment of disease activity
Numerical scale of 1–10:
1 representing very bad,
10 representing excellent
7 (1) 8 (1)
DAS28-ESR 3.1 (2.6) 4.0 (2.5)
BASDAI 4.5 (2.0)
C-reactive protein (μg/mL) 1.9 (4.1) 1.5 (2.0) 1.5 (5.3) 1.0 (7.2) 1.1 (2.9)
Fecal calprotectin (μg/g) 85.0 (204.8) 108 (1077.5)
ESR (mm/h) 14.0 (13.0) 9.0 (27.0) 15.0 (14.0)
IFX trough (μg/mL) 4.4 (4.3) 3.9 (4.1) 5.1 (9.0) 7.6 (20.5) 6.5 (8.0)
Positive IFX NABs (%) 4/73 (5.5) 1/28 (3.6) 0 0 0
§Azathioprine, mercaptopurine, thioguanin, methotrexate, leflunomide, and sulfasalazine. Mean ± standard deviations are presented above for normally
distributed variables. N (%) for categorical variables. Median and (interquartile range) for non-normally distributed variables
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three with UC after a median number of one and three infu-
sions, respectively. All patients were switched to other than
infliximab therapy. Five of these seven patients, four with CD
and one with UC, ceased their therapy in the presence of
neutralizing antibody formation against infliximab originator,
and, subsequently against biosimilar infliximab. At the time of
transition, neutralizing antibody formation against infliximab
was asymptomatic (and unknown due to delay in laboratory
test results). Non-responding patients were not observed in
any of the rheumatological indications.
Nocebo
Sixteen patients were designated as nocebo patients, thirteen
and three patients for IBD and rheumatological indications,
respectively. This resulted in an overall nocebo rate of 12.8%
(16/125) and when specified for rheumatological and IBD
indications, a similar rate was observed (12.5% (3/24) and
12.9% (13/101), respectively). Eight and five nocebo-
response patients with CD and UC discontinued infliximab
biosimilar therapy after a median number of three and four
infusions. Additionally, a feeling of less exerted effect, chills
during infusions, and numbness of facial skin with tingling
limbs were reported in these patients. In rheumatological in-
dications, one rheumatoid arthritis and two ankylosing spon-
dylitis patients discontinued infliximab biosimilar therapy due
to a nocebo response following a single infusion with
infliximab biosimilar. A perceived diminished effect and
new-onset headache were reported in these patients. All IBD
and rheumatological nocebo-response patients were success-
fully treated with at least two additional infusions of (re-
initiated) infliximab originator.
Longitudinal trend of treatment outcome parameters
In IBD as well as rheumatological patients, no statistically
significant longitudinal change in disease activity assess-
ments, kinetics, and laboratory outcomes was found. This is
elaborated in Table 2. Only patient’s assessment of disease
activity in UC patients appeared to decrease in a statistically
significant way (p = 0.027), whilst laboratory and kinetic data
showed no statistically significant change over time.
Conclusion and discussion
In this pragmatic trial, we monitored effectiveness and
safety in immune-mediated inflammatory disease patients,
who switched from originator infliximab to biosimilar fo-
cusing on nocebo response, together with a biosimilar im-
plementation strategy to optimize a shared therapeutic de-
cision with individual patients. Core element of decision-
making between doctor and patient was an informed
consent, allegedly to decrease nocebo response next to em-
powerment of patients. Infliximab batch-number informa-
tion was registered to objectify individual therapeutic find-
ings for idiosyncratic or medication batch-specific effects,
beyond the general statistical data.
Similarity in effectiveness, antibody-to-infliximab, and the
adverse drug reaction profile was corroborated in these series
consistent with findings from others [2, 3, 16, 17]. We ob-
served an overall nocebo-response rate of 12.8% that not
differed between IBD and rheumatological patient groups.
As a consequence of a single center study, small numbers
of patients with rheumatological indications were included
in this series. Although commonly not quantified or reported
by means of objective disease outcome measures, non-
medical switching may still have a negative impact on pa-
tient’s perceived disease burden. The NORSWITCH study, a
52-week randomized clinical non-inferiority trial that com-
pared originator infliximab to biosimilar included IMID pa-
tients and reported disease flare rates after switch of 26 and
30% for originator and biosimilar, respectively [3]. These
numbers may reflect nocebo effect as a result of non-
medical switching, at least in part, however, the authors did
not specify this. The percentage of patients with a nocebo
response observed in this study with a mixed IMID popula-
tion is higher than that reported in the observational non-
medical infliximab switch study of the DANBIO registry
considering rheumatological patients [16]. The authors only
reported a 3.4% lower rate in drug retention for patients on
biosimilar infliximab after 413 days when compared to orig-
inator infliximab. This observation was attributed to a possi-
ble nocebo effect. Our findings are in line with other real-
world data provided by an observational single clinic study
performed in Norway [18]. In this study, 39 rheumatoid ar-
thritis and ankylosing spondylitis patients on originator
infliximab were switched to biosimilar and a nocebo-
response effect of 15% after a median of 11 months was
reported [18].
Although our study is not controlled for measuring the
nocebo-response effect of shared decision-making, we hypo-
thetically propose that patient empowerment may decrease
nocebo-response rate, whilst effectiveness and safety are
maintained. Furthermore, extra safety provided by intensive
monitoring on individual basis may give non-medical
biosimilar switching an additional gain.
The objective of implementing biosimilars is economi-
cally driven [19]. In our series, for example, the estimated
loss of financial gain by transition into biosimilar is not
only influenced by the described nocebo-effect rate. The
percentage of patients not willing to switch (14.4%), the
nocebo-effect rate (13%) together with implementation
costs drove the overall drug cost reduction on a population
level below 37% given a biosimilar price reduction of 50%
by no originator drug discount.
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We therefore suggest that full implementation of
biosimilars in naïve patients could be an attractive economical
strategy without further risking non-specific treatment effects
in certain patient groups by switching [19]. This particularly
holds true for biologicals with a limited period of use.
Infliximab, indeed seems to be used for long periods in only
few patients, treatment discontinuation rates are approximate-
ly 15% per year in the first years after starting infliximab
therapy in IBD as well as rheumatology indications [16, 20].
The objective of the described biosimilar implementation
was to obtain individualized treatment decisions based on ac-
tuary data on effectiveness and safety provided by a registry.
We observed nocebo effects and propose its use as a treatment
quality assessment of patient’s acceptance in any switch
concerning biosimilars or second-line biologics. Prospective
evidence is warranted to conclude if shared decision-making
and patient empowerment could reduce the nocebo-effect rate.
Further research comprising larger data sets in particular with
patient-reported outcomes is needed to elucidate which patient
aspects influence the nocebo effect in order to stratify for
patients who are more prone to the effect. Although the main
objective was not to study infliximab, biosimilar effectiveness
and safety the amount of included patients, especially in rheu-
matological indications, can be regarded as a limit.
In conclusion, until now, there is sparse data on the practi-
cal implementation of non-medical switching and for
biosimilar transition in particular. In our series with IBD and
rheumatological patients, we demonstrated effectiveness and
safety on the transition into biosimilar infliximab, whilst using
a protocol involving informed consent from patients for non-
medical switching. Success of non-medical biosimilar switch
in terms of beneficial clinical, pharmacological, and even eco-
nomical effects are relevantly/critically influenced by the
nocebo-response effect rate.
In addition, a quality database registration on effectiveness,
safety, kinetics, laboratory parameters, and medication-batch
data seemed pivotal for follow-up of changes in medication
strategy and safety on both individual as well as population
level regarding biosimilar transition, reflecting an accurate
nocebo assessment and quantification. This also contributed
to shared decision-making and individualized medicine.
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Table 2 Overview of differences (95% CI) at a linear trend in efficacy and laboratory data per indication after switching to biosimilar infliximab
compared to baseline data. Introducing a patient-specific random intercept made the correction of repeated measurements within a patient
CD UC RA + PsoA§ AS
Patient’s assessment of disease
activity numerical scale of 1–10:
1 representing very bad, 10
representing excellent
− 1.08 (−2.19–0.04) − 2.10 (− 3.95 to − 0.25)* – –
DAS28-ESR − 1.28 (− 3.40–0.84) –
BASDAI – − 0.52 (− 4.55–3.51)
C-reactive protein (μg/mL) − 2.20 (− 8.09–3.69) 4.28 (− 0.84–9.40) − 3.39 (− 9.92–3.14) 0.12 (− 8.52–8.76)
ESR (mm/h) – – 0.92 (− 14.53–16.38) − 5.24 (− 12.60–2.12)
Fecal calprotectin (μg/g) − 256.62 (− 760.72–247.47) − 370.53 (− 1814.85–1073.80)
IFX trough (μg/mL) 0.61 (− 3.77–4.99) 1.12 (− 0.50–2.74) 4.11 (− 5.72–13.94) − 1.18 (− 7.01–4.64)
* A p-value smaller than 0.05 was found and considered as statistically significant. These data comprises measurements in responder, non-responder and
nocebo-effect response patients. Differences found are expressed as mean annual change. Crohn’s disease (CD), ulcerative colitis (UC), rheumatoid
arthritis (RA), psoriatic arthritis (PsoA), and ankylosing spondylitis (AS).
§ Data in these indications are reported as one due to limited patient sample sizes per indication
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